<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36010630</PMID><DateCompleted><Year>2022</Year><Month>08</Month><Day>29</Day></DateCompleted><DateRevised><Year>2022</Year><Month>12</Month><Day>07</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2073-4409</ISSN><JournalIssue CitedMedium="Internet"><Volume>11</Volume><Issue>16</Issue><PubDate><Year>2022</Year><Month>Aug</Month><Day>17</Day></PubDate></JournalIssue><Title>Cells</Title><ISOAbbreviation>Cells</ISOAbbreviation></Journal><ArticleTitle>Effect of Ultra-Micronized Palmitoylethanolamide and Luteolin on Olfaction and Memory in Patients with Long COVID: Results of a Longitudinal Study.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">2552</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/cells11162552</ELocationID><Abstract><AbstractText>In this study, we investigated whether treatment with palmitoylethanolamide and luteolin (PEA-LUT) leads to improvement in the quantitative or qualitative measures of olfactory dysfunction or relief from mental clouding in patients affected by long COVID. Patients with long COVID olfactory dysfunction were allocated to different groups based on the presence ("previously treated") or absence ("na&#xef;ve") of prior exposure to olfactory training. Patients were then randomized to receive PEA-LUT alone or in combination with olfactory training. Olfactory function and memory were assessed at monthly intervals using self-report measures and quantitative thresholds. A total of 69 patients (43 women, 26 men) with an age average of 40.6 + 10.5 were recruited. PEA-LUT therapy was associated with a significant improvement in validated odor identification scores at the baseline versus each subsequent month; assessment at 3 months showed an average improvement of 10.7 + 2.6, CI 95%: 6-14 (<i>p</i> &lt; 0.0001). The overall prevalence of parosmia was 79.7% (55 patients), with a significant improvement from the baseline to 3 months (<i>p</i> &lt; 0.0001), namely in 31 patients from the Na&#xef;ve 1 group (72%), 15 from the Na&#xef;ve 2 group (93.7%), and 9 from the remaining group (90%). Overall, mental clouding was detected in 37.7% (26 subjects) of the cases, with a reduction in severity from the baseline to three months (<i>p</i> = 0.02), namely in 15 patients from the Na&#xef;ve 1 group (34.8%), 7 from the Na&#xef;ve 2 group (43.7%), and 4 from the remaining group (40%). Conclusions. In patients with long COVID and chronic olfactory loss, a regimen including oral PEA-LUT and olfactory training ameliorated olfactory dysfunction and memory. Further investigations are necessary to discern biomarkers, mechanisms, and long-term outcomes.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>De Luca</LastName><ForeName>Pietro</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0002-6505-1680</Identifier><AffiliationInfo><Affiliation>Department of Medicine, Surgery and Dentistry, University of Salerno, Baronissi, 84081 Salerno, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Otolaryngology Department, San Giovanni-Addolorata Hospital, 00184 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Camaioni</LastName><ForeName>Angelo</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Otolaryngology Department, San Giovanni-Addolorata Hospital, 00184 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marra</LastName><ForeName>Pasquale</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0002-3491-8069</Identifier><AffiliationInfo><Affiliation>Department of Medicine, Surgery and Dentistry, University of Salerno, Baronissi, 84081 Salerno, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Salzano</LastName><ForeName>Giovanni</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0003-3947-8733</Identifier><AffiliationInfo><Affiliation>ENT and Maxillofacial Surgery Unit, Istituto Tumori G. Pascale of Naples, 80131 Naples, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carriere</LastName><ForeName>Giovanni</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Otolaryngology, Ars Medica, 00100 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ricciardi</LastName><ForeName>Luca</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0001-5110-8386</Identifier><AffiliationInfo><Affiliation>Division of Neurosurgery, Sant'Andrea Hospital, Department of Neuroscience, Mental Health and Sense Organs (NESMOS), Sapienza University of Rome, 00189 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pucci</LastName><ForeName>Resi</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0001-6237-2334</Identifier><AffiliationInfo><Affiliation>Oral and Maxillofacial, San Camillo Hospital, 00152 Rome, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Oral and Maxillofacial Science, Sapienza University of Rome, 00185 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Montemurro</LastName><ForeName>Nicola</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0002-3686-8907</Identifier><AffiliationInfo><Affiliation>Department of Neurosurgery, Pisana University Hospital, University of Pisa, 56124 Pisa, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brenner</LastName><ForeName>Michael J</ForeName><Initials>MJ</Initials><Identifier Source="ORCID">0000-0003-4926-0957</Identifier><AffiliationInfo><Affiliation>Department of Otolaryngology-Head and Neck Surgery, University of Michigan Medical School, Ann Arbor, MI 48109, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Di Stadio</LastName><ForeName>Arianna</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-5510-3814</Identifier><AffiliationInfo><Affiliation>Department of GF Ingrassia, Via di Santa Sofia 87, University of Catania, 95123 Catania, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neuroinflammation Lab, UCL Queen Square Neurology, London WC1N 1PJ, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>08</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Cells</MedlineTA><NlmUniqueID>101600052</NlmUniqueID><ISSNLinking>2073-4409</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000577">Amides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004983">Ethanolamines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010169">Palmitic Acids</NameOfSubstance></Chemical><Chemical><RegistryNumber>6R8T1UDM3V</RegistryNumber><NameOfSubstance UI="C005958">palmidrol</NameOfSubstance></Chemical><Chemical><RegistryNumber>KUX1ZNC9J2</RegistryNumber><NameOfSubstance UI="D047311">Luteolin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000577" MajorTopicYN="N">Amides</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004983" MajorTopicYN="N">Ethanolamines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D047311" MajorTopicYN="N">Luteolin</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000857" MajorTopicYN="Y">Olfaction Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010169" MajorTopicYN="N">Palmitic Acids</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012903" MajorTopicYN="N">Smell</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000093485" MajorTopicYN="Y">COVID-19 Drug Treatment</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">PEA-LUT</Keyword><Keyword MajorTopicYN="N">anosmia</Keyword><Keyword MajorTopicYN="N">brain fog</Keyword><Keyword MajorTopicYN="N">hyposmia</Keyword><Keyword MajorTopicYN="N">long-haul COVID syndrome</Keyword><Keyword MajorTopicYN="N">lutein</Keyword><Keyword MajorTopicYN="N">memory</Keyword><Keyword MajorTopicYN="N">mental clouding</Keyword><Keyword MajorTopicYN="N">neuroinflammation</Keyword><Keyword MajorTopicYN="N">olfactory threshold</Keyword><Keyword MajorTopicYN="N">olfactory training</Keyword><Keyword MajorTopicYN="N">palmitoylethanolamide</Keyword><Keyword MajorTopicYN="N">parosmia</Keyword><Keyword MajorTopicYN="N">post-acute sequelae of SARS-CoV-2 infection (PASC)</Keyword><Keyword MajorTopicYN="N">qualitative smell disorders</Keyword><Keyword MajorTopicYN="N">smell disorders</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>6</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>8</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>8</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>8</Month><Day>26</Day><Hour>1</Hour><Minute>12</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>8</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>8</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>8</Month><Day>17</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36010630</ArticleId><ArticleId IdType="pmc">PMC9406356</ArticleId><ArticleId IdType="doi">10.3390/cells11162552</ArticleId><ArticleId IdType="pii">cells11162552</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Tenforde M.W., Kim S.S., Lindsell C.J., Rose E.B., Shapiro N.I., Files D.C., Gibbs K.W., Erickson H.L., Steingrub J.S., Smithline H.A., et al. CDC COVID-19 Response Team. IVY Network Investigators Symptom Duration and Risk Factors for Delayed Return to Usual Health Among Outpatients with COVID-19 in a Multistate Health Care Systems Network United States, March&#x2013;June 2020. MMWR Morb. Mortal. Wkly. Rep. 2020;69:993&#x2013;998. doi: 10.15585/mmwr.mm6930e1.</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm6930e1</ArticleId><ArticleId IdType="pmc">PMC7392393</ArticleId><ArticleId IdType="pubmed">32730238</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Stadio A., D&#x2019;Ascanio L., Vaira L.A., Cantone E., De Luca P., Cingolani C., Motta G., De Riu G., Vitelli F., Spriano G., et al. Ultramicronized Palmitoylethanolamide and Luteolin Supplement Combined with Olfactory Training to Treat Post-COVID-19 Olfactory Impairment: A Multi-Center Double-Blinded Randomized Placebo-Controlled Clinical Trial. Curr. Neuropharmacol. 2022 doi: 10.2174/1570159X20666220420113513. Epub ahead of print .</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1570159X20666220420113513</ArticleId><ArticleId IdType="pmc">PMC9886808</ArticleId><ArticleId IdType="pubmed">35450527</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwabenland M., Sali&#xe9; H., Tanevski J., Killmer S., Lago M.S., Schlaak A.E., Mayer L., Matschke J., P&#xfc;schel K., Fitzek A., et al. Deep spatial profiling of human COVID-19 brains reveals neuroinflammation with distinct microanatomical microglia-T-cell interactions. Immunity. 2021;54:1594&#x2013;1610.e11. doi: 10.1016/j.immuni.2021.06.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2021.06.002</ArticleId><ArticleId IdType="pmc">PMC8188302</ArticleId><ArticleId IdType="pubmed">34174183</ArticleId></ArticleIdList></Reference><Reference><Citation>Rogers J.P., Chesney E., Oliver D., Pollak T.A., McGuire P., Fusar-Poli P., Zandi M.S., Lewis G., David A.S. Psychiatric and neuropsychiatric presentations associated with severe coronavirus infections: A systematic review and meta-analysis with comparison to the COVID-19 pandemic. Lancet Psychiatry. 2020;7:611&#x2013;627. doi: 10.1016/S2215-0366(20)30203-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2215-0366(20)30203-0</ArticleId><ArticleId IdType="pmc">PMC7234781</ArticleId><ArticleId IdType="pubmed">32437679</ArticleId></ArticleIdList></Reference><Reference><Citation>Calabria M., Garc&#xed;a-S&#xe1;nchez C., Grunden N., Pons C., Arroyo J.A., G&#xf3;mez-Anson B., Garc&#xed;a M.d.C.E., Belv&#xed;s R., Moroll&#xf3;n N., Igual J.V., et al. Post-COVID-19 fatigue: The contribution of cognitive and neuropsychiatric symptoms. J. Neurol. 2022;269:3990&#x2013;3999. doi: 10.1007/s00415-022-11141-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-022-11141-8</ArticleId><ArticleId IdType="pmc">PMC9055007</ArticleId><ArticleId IdType="pubmed">35488918</ArticleId></ArticleIdList></Reference><Reference><Citation>De Luca P., Scarpa A., Ralli M., Tassone D., Simone M., De Campora L., Cassandro C., Di Stadio A. Auditory Disturbances and SARS-CoV-2 Infection: Brain Inflammation or Cochlear Affection? Systematic Review and Discussion of Potential Pathogenesis. Front. Neurol. 2021;12:1234. doi: 10.3389/fneur.2021.707207.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2021.707207</ArticleId><ArticleId IdType="pmc">PMC8373381</ArticleId><ArticleId IdType="pubmed">34421805</ArticleId></ArticleIdList></Reference><Reference><Citation>Iaconetta G., De Luca P., Scarpa A., Cassandro C., Cassandro E. Meningoencephalitis associated with SARS-CoV-2. Transl. Med. Unisa. 2020;23:8. doi: 10.37825/2239-9747.1007.</Citation><ArticleIdList><ArticleId IdType="doi">10.37825/2239-9747.1007</ArticleId><ArticleId IdType="pmc">PMC8370532</ArticleId><ArticleId IdType="pubmed">33457322</ArticleId></ArticleIdList></Reference><Reference><Citation>Douaud G., Lee S., Alfaro-Almagro F., Arthofer C., Wang C., McCarthy P., Lange F., Andersson J.L., Griffanti L., Duff E., et al. SARS-CoV-2 is associated with changes in brain structure in UK Biobank. Nature. 2022;604:697&#x2013;707. doi: 10.1038/s41586-022-04569-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-04569-5</ArticleId><ArticleId IdType="pmc">PMC9046077</ArticleId><ArticleId IdType="pubmed">35255491</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Stadio A., Brenner M.J., De Luca P., Albanese M., D&#x2019;Ascanio L., Ralli M., Roccamatisi D., Cingolani C., Vitelli F., Camaioni A., et al. Olfactory Dysfunction, Headache, and Mental Clouding in Adults with Long-COVID-19: What Is the Link between Cognition and Olfaction? A Cross-Sectional Study. Brain Sci. 2022;12:154. doi: 10.3390/brainsci12020154.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/brainsci12020154</ArticleId><ArticleId IdType="pmc">PMC8870047</ArticleId><ArticleId IdType="pubmed">35203918</ArticleId></ArticleIdList></Reference><Reference><Citation>Peritore A., D&#x2019;Amico R., Siracusa R., Cordaro M., Fusco R., Gugliandolo E., Genovese T., Crupi R., Di Paola R., Cuzzocrea S., et al. Management of Acute Lung Injury: Palmitoylethanolamide as a New Approach. Int. J. Mol. Sci. 2021;22:5533. doi: 10.3390/ijms22115533.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms22115533</ArticleId><ArticleId IdType="pmc">PMC8197255</ArticleId><ArticleId IdType="pubmed">34073872</ArticleId></ArticleIdList></Reference><Reference><Citation>Noce A., Albanese M., Marrone G., Di Lauro M., Pietroboni Zaitseva A., Palazzetti D., Guerriero C., Paolino A., Pizzenti G., Di Daniele F., et al. Ultramicronized Palmitoylethanolamide (um-PEA): A New Possible Adjuvant Treatment in COVID-19 patients. Pharmaceuticals. 2021;14:336. doi: 10.3390/ph14040336.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ph14040336</ArticleId><ArticleId IdType="pmc">PMC8067485</ArticleId><ArticleId IdType="pubmed">33917573</ArticleId></ArticleIdList></Reference><Reference><Citation>Albanese M., Marrone G., Paolino A., Di Lauro M., Di Daniele F., Chiaramonte C., D&#x2019;Agostini C., Romani A., Cavaliere A., Guerriero C., et al. Effects of Ultramicronized Palmitoylethanolamide (um-PEA) in COVID-19 Early Stages: A Case&#x2013;Control Study. Pharmaceuticals. 2022;15:253. doi: 10.3390/ph15020253.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ph15020253</ArticleId><ArticleId IdType="pmc">PMC8878249</ArticleId><ArticleId IdType="pubmed">35215365</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Stadio A., D&#x2019;Ascanio L., De Luca P., Roccamatisi D., La Mantia I., Brenner M.J. Hyperosmia after COVID-19: Hedonic percep-tion or hypersensitivity? Eur. Rev. Med. Pharmacol. Sci. 2022;26:2196&#x2013;2200. doi: 10.26355/eurrev_202203_28368.</Citation><ArticleIdList><ArticleId IdType="doi">10.26355/eurrev_202203_28368</ArticleId><ArticleId IdType="pubmed">35363370</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Stadio A., D&#x2019;Ascanio L., La Mantia I., Ralli M., Brenner M.J. Parosmia after COVID-19: Olfactory training, neuroinflammation and distortions of smell. Eur. Rev. Med. Pharmacol. Sci. 2022;26:1&#x2013;3. doi: 10.26355/eurrev_202201_27739.</Citation><ArticleIdList><ArticleId IdType="doi">10.26355/eurrev_202201_27739</ArticleId><ArticleId IdType="pubmed">35049034</ArticleId></ArticleIdList></Reference><Reference><Citation>Baraniuk J.N., Merck S.J. Neuroregulation of Human Nasal Mucosa. Ann. N. Y. Acad. Sci. 2009;1170:604&#x2013;609. doi: 10.1111/j.1749-6632.2009.04481.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1749-6632.2009.04481.x</ArticleId><ArticleId IdType="pmc">PMC4209299</ArticleId><ArticleId IdType="pubmed">19686200</ArticleId></ArticleIdList></Reference><Reference><Citation>De Silva N.M.L., Barros-Arag&#xe3;o F.G., De Felice F.G., Ferreira S.T. Inflammation at the crossroads of COVID-19, cognitive deficits and depression. Neuropharmacology. 2022;209:109023. doi: 10.1016/j.neuropharm.2022.109023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuropharm.2022.109023</ArticleId><ArticleId IdType="pmc">PMC8894741</ArticleId><ArticleId IdType="pubmed">35257690</ArticleId></ArticleIdList></Reference><Reference><Citation>Facchinetti R., Valenza M., Bronzuoli M.R., Menegoni G., Ratano P., Steardo L., Campolongo P., Scuderi C. Looking for a Treatment for the Early Stage of Alzheimer&#x2019;s Disease: Preclinical Evidence with Co-Ultramicronized Palmitoylethanolamide and Luteolin. Int. J. Mol. Sci. 2020;21:3802. doi: 10.3390/ijms21113802.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms21113802</ArticleId><ArticleId IdType="pmc">PMC7312730</ArticleId><ArticleId IdType="pubmed">32471239</ArticleId></ArticleIdList></Reference><Reference><Citation>Glachet O., Moustafa A.A., Gallouj K., El Haj M. Smell your memories: Positive effect of odor exposure on recent and remote autobiographical memories in Alzheimer&#x2019;s disease. J. Clin. Exp. Neuropsychol. 2019;41:555&#x2013;564. doi: 10.1080/13803395.2019.1586840.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/13803395.2019.1586840</ArticleId><ArticleId IdType="pubmed">30890017</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#x2019;Ascanio L., Vitelli F., Cingolani C., Maranzano M., Brenner M.J., Di Stadio A. Randomized clinical trial &#x201c;olfactory dysfunction after COVID-19: Olfactory rehabilitation therapy vs. intervention treatment with Palmitoylethanolamide and Luteolin&#x201d;: Preliminary results. Eur. Rev. Med. Pharmacol. Sci. 2021;25:4156&#x2013;4162. doi: 10.26355/eurrev_202106_26059.</Citation><ArticleIdList><ArticleId IdType="doi">10.26355/eurrev_202106_26059</ArticleId><ArticleId IdType="pubmed">34156697</ArticleId></ArticleIdList></Reference><Reference><Citation>Sigurdardottir S., Andelic N., Skandsen T., Anke A., Roe C., Holthe O.O., Wehling E. Olfactory Identification and Its Relationship to Executive Functions, Memory, and Disability 1 Year After Severe Traumatic Brain Injury. Neuropsychology. 2016;30:98&#x2013;108. doi: 10.1037/neu0000206.</Citation><ArticleIdList><ArticleId IdType="doi">10.1037/neu0000206</ArticleId><ArticleId IdType="pubmed">26076319</ArticleId></ArticleIdList></Reference><Reference><Citation>Mydlikowska-&#x15a;mig&#xf3;rska A., &#x15a;mig&#xf3;rski K., Szcze&#x15b;niak D., Rymaszewska J. Can olfactory training support improvement of memory functioning in patients with cognitive disorders? Psychiatr. Pol. 2020;184:1&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pubmed">35988083</ArticleId></ArticleIdList></Reference><Reference><Citation>Petrosino S., Di Marzo V. The pharmacology of palmitoylethanolamide and first data on the therapeutic efficacy of some of its new formulations. J. Cereb. Blood Flow Metab. 2016;174:1349&#x2013;1365. doi: 10.1111/bph.13580.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bph.13580</ArticleId><ArticleId IdType="pmc">PMC5429331</ArticleId><ArticleId IdType="pubmed">27539936</ArticleId></ArticleIdList></Reference><Reference><Citation>Bartlett J.A., van der Voort Maarschalk K. Understanding the Oral Mucosal Absorption and Resulting Clinical Pharmacokinetics of Asenapine. AAPS PharmSciTech. 2012;13:1110&#x2013;1115. doi: 10.1208/s12249-012-9839-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1208/s12249-012-9839-7</ArticleId><ArticleId IdType="pmc">PMC3513449</ArticleId><ArticleId IdType="pubmed">22936407</ArticleId></ArticleIdList></Reference><Reference><Citation>Gugliandolo E., Peritore A.F., Piras C., Cuzzocrea S., Crupi R. Palmitoylethanolamide and Related ALIAmides: Prohomeostatic Lipid Compounds for Animal Health and Wellbeing. Vet. Sci. 2020;7:78. doi: 10.3390/vetsci7020078.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vetsci7020078</ArticleId><ArticleId IdType="pmc">PMC7355440</ArticleId><ArticleId IdType="pubmed">32560159</ArticleId></ArticleIdList></Reference><Reference><Citation>Luongo L., Guida F., Boccella S., Bellini G., Gatta L., Rossi F., de Novellis V., Maione S. Palmitoylethanolamide reduces formalin-induced neuropathic-like behaviour through spinal glial/microglial phenotypical changes in mice. CNS Neurol. Disord. Drug Targets. 2013;12:45&#x2013;54. doi: 10.2174/1871527311312010009.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1871527311312010009</ArticleId><ArticleId IdType="pubmed">23394524</ArticleId></ArticleIdList></Reference><Reference><Citation>De Luca P., Marra P., La Mantia I., Salzano F.A., Camaioni A., Di Stadio A. Entorhinal Cortex and Persistent Olfactory Loss in COVID-19 Patients: A Neuroanatomical Hypothesis. Comment on Fiorentino et al. Correlations between Persistent Olfactory and Semantic Memory Disorders after SARS-CoV-2 Infection. Brain Sci. 2022;12:850. doi: 10.3390/brainsci12070850.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/brainsci12070850</ArticleId><ArticleId IdType="pmc">PMC9313352</ArticleId><ArticleId IdType="pubmed">35884657</ArticleId></ArticleIdList></Reference><Reference><Citation>Skaper S.D., Facci L., Giusti P. Mast cells, glia and neuroinflammation: Partners in crime? Immunology. 2014;141:314&#x2013;327. doi: 10.1111/imm.12170.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/imm.12170</ArticleId><ArticleId IdType="pmc">PMC3930370</ArticleId><ArticleId IdType="pubmed">24032675</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#x2019;Amico R., Impellizzeri D., Cuzzocrea S., Di Paola R. ALIAmides Update: Palmitoylethanolamide and Its Formulations on Management of Peripheral Neuropathic Pain. Int. J. Mol. Sci. 2020;21:5330. doi: 10.3390/ijms21155330.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms21155330</ArticleId><ArticleId IdType="pmc">PMC7432736</ArticleId><ArticleId IdType="pubmed">32727084</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Stadio A., Angelini C. Microglia polarization by mitochondrial metabolism modulation: A therapeutic opportunity in neurodegenerative diseases. Mitochondrion. 2019;46:334&#x2013;336. doi: 10.1016/j.mito.2018.09.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mito.2018.09.003</ArticleId><ArticleId IdType="pubmed">30243831</ArticleId></ArticleIdList></Reference><Reference><Citation>Campolo M., Crupi R., Cordaro M., Cardali S.M., Ardizzone A., Casili G., Scuderi S.A., Siracusa R., Esposito E., Conti A., et al. Co-Ultra PEALut Enhances Endogenous Repair Response Following Moderate Traumatic Brain Injury. Int. J. Mol. Sci. 2021;22:8717. doi: 10.3390/ijms22168717.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms22168717</ArticleId><ArticleId IdType="pmc">PMC8395716</ArticleId><ArticleId IdType="pubmed">34445417</ArticleId></ArticleIdList></Reference><Reference><Citation>Contarini G., Franceschini D., Facci L., Barbierato M., Giusti P., Zusso M. A co-ultramicronized palmitoylethanolamide/luteolin composite mitigates clinical score and disease-relevant molecular markers in a mouse model of experimental autoimmune encephalomyelitis. J. Neuroinflamm. 2019;16:126. doi: 10.1186/s12974-019-1514-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12974-019-1514-4</ArticleId><ArticleId IdType="pmc">PMC6587257</ArticleId><ArticleId IdType="pubmed">31221190</ArticleId></ArticleIdList></Reference><Reference><Citation>Cordaro M., Cuzzocrea S., Crupi R. An Update of Palmitoylethanolamide and Luteolin Effects in Preclinical and Clinical Studies of Neuroinflammatory Events. Antioxidants. 2020;9:216. doi: 10.3390/antiox9030216.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/antiox9030216</ArticleId><ArticleId IdType="pmc">PMC7139331</ArticleId><ArticleId IdType="pubmed">32150935</ArticleId></ArticleIdList></Reference><Reference><Citation>Landolfo E., Cutuli D., Petrosini L., Caltagirone C. Effects of Palmitoylethanolamide on Neurodegenerative Diseases: A Review from Rodents to Humans. Biomolecules. 2022;12:667. doi: 10.3390/biom12050667.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biom12050667</ArticleId><ArticleId IdType="pmc">PMC9138306</ArticleId><ArticleId IdType="pubmed">35625595</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>